{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:54:02Z","timestamp":1787237642483,"version":"build-2736575974"},"reference-count":185,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Polycystic ovary syndrome (PCOS) is characterized by elevated androgen production and subclinical changes in cardiovascular and metabolic risk markers. Total cholesterol, high-density lipoprotein (HDL) cholesterol, fasting glucose, and fasting insulin appear to increase specifically in PCOS compared with fertile women. PCOS also confers an increased risk of cardiometabolic disease in later life. Novel biomarkers such as serum\u2019s cholesterol efflux capacity and blood-derived macrophage activation profile may assist in more accurately defining the cardiometabolic risk profile in these women. Aldosterone antagonists, androgen receptor antagonists, 5\u03b1-reductase inhibitors, and synthetic progestogens are used to reduce hyperandrogenism. Because increased insulin secretion enhances ovarian androgen production, short-term treatment with metformin and other hypoglycemic agents results in significant weight loss, favorable metabolic changes, and testosterone reduction. The naturally occurring inositols display insulin-sensitizing effects and may be also used in this context because of their safety profile. Combined oral contraceptives represent the drug of choice for correction of androgen-related symptoms. Overall, PCOS management remains focused on specific targets including assessment and treatment of cardiometabolic risk, according to disease phenotypes. While new options are adding to established therapeutic approaches, a sometimes difficult balance between efficacy and safety of available medications has to be found in individual women.<\/jats:p>","DOI":"10.3390\/ijms21249554","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T21:11:02Z","timestamp":1608066662000},"page":"9554","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4820-4876","authenticated-orcid":false,"given":"Andrea","family":"Cignarella","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5647-1157","authenticated-orcid":false,"given":"Roberto","family":"Mioni","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Padova, 35128 Padova, Italy"},{"name":"Clinica Medica 3, University Hospital, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Sabbadin","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Padova, 35128 Padova, Italy"},{"name":"Endocrinology Unit, University Hospital, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Dassie","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Padova, 35128 Padova, Italy"},{"name":"Clinica Medica 3, University Hospital, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Parolin","sequence":"additional","affiliation":[{"name":"Internal Medicine 2, Ca\u2019 Foncello Hospital, ULSS2 Marca Trevigiana, 31100 Treviso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Vettor","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Padova, 35128 Padova, Italy"},{"name":"Clinica Medica 3, University Hospital, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-5727","authenticated-orcid":false,"given":"Mattia","family":"Barbot","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Padova, 35128 Padova, Italy"},{"name":"Endocrinology Unit, University Hospital, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Scaroni","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Padova, 35128 Padova, Italy"},{"name":"Endocrinology Unit, University Hospital, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"16057","DOI":"10.1038\/nrdp.2016.57","article-title":"Polycystic ovary syndrome","volume":"2","author":"Azziz","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nrendo.2018.24","article-title":"Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment","volume":"14","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMcp1514916","article-title":"Clinical practice\u2013polycystic ovary syndrome","volume":"375","author":"McCartney","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1210\/jcem.87.5.8471","article-title":"Menstrual cycle irregularity and risk for future cardiovascular disease","volume":"87","author":"Solomon","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.tcm.2019.08.010","article-title":"Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention","volume":"30","author":"Osibogun","year":"2020","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2337\/dc18-1738","article-title":"The impact of obesity on the incidence of type 2 diabetes among women with polycystic ovary syndrome","volume":"42","author":"Kakoly","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1093\/humrep\/del003","article-title":"Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin","volume":"21","author":"Paterakis","year":"2006","journal-title":"Hum. Reprod."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1210\/er.2011-1034","article-title":"Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications","volume":"33","author":"Dunaif","year":"2012","journal-title":"Endocr. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.fertnstert.2018.05.004","article-title":"International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"110","author":"Teede","year":"2018","journal-title":"Fertil. Steril."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/CIRCULATIONAHA.119.043429","article-title":"The use of sex-specific factors in the assessment of women\u2019s cardiovascular risk","volume":"141","author":"Agarwala","year":"2020","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/1471-0528.16171","article-title":"Cardio-metabolic risk factors among young infertile women: A systematic review and meta-analysis","volume":"127","author":"Mulder","year":"2020","journal-title":"BJOG"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"R238","DOI":"10.1530\/EC-18-0129","article-title":"Cardiometabolic risk in polycystic ovary syndrome","volume":"7","author":"Pfeifer","year":"2018","journal-title":"Endocr. Connect."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCRESAHA.117.311071","article-title":"Resident and monocyte-derived macrophages in cardiovascular disease","volume":"122","author":"Honold","year":"2018","journal-title":"Circ. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1161\/ATVBAHA.113.301328","article-title":"Macrophage function and polarization in cardiovascular disease: A role of estrogen signaling?","volume":"33","author":"Bolego","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1210\/jc.2014-2751","article-title":"Alternative activation of human macrophages is rescued by estrogen treatment in vitro and impaired by menopausal status","volume":"100","author":"Toniolo","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2213-8587(15)00126-6","article-title":"Association of HDL cholesterol efflux capacity with incident coronary heart disease events: A prospective case-control study","volume":"3","author":"Saleheen","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"E841","DOI":"10.1210\/jc.2013-3918","article-title":"Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS","volume":"99","author":"Roe","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/cen.13310","article-title":"Impact of hormonal contraception and weight loss on high-density lipoprotein cholesterol efflux and lipoprotein particles in women with polycystic ovary syndrome","volume":"86","author":"Dokras","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s12020-019-01911-2","article-title":"Activation profiles of monocyte-macrophages and HDL function in healthy women in relation to menstrual cycle and in polycystic ovary syndrome patients","volume":"66","author":"Tedesco","year":"2019","journal-title":"Endocrine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/humrep\/deu115","article-title":"Polycystic ovary syndrome influences the level of serum amyloid A and activity of phospholipid transfer protein in HDL2 and HDL3","volume":"29","author":"Gidwani","year":"2014","journal-title":"Hum. Reprod."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Bonacina, F., Da Dalt, L., Catapano, A.L., and Norata, G.D. (2020). Metabolic adaptations of cells at the vascular-immune interface during atherosclerosis. Mol. Asp. Med., 100918.","DOI":"10.1016\/j.mam.2020.100918"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s12020-014-0340-9","article-title":"Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients","volume":"48","author":"Albu","year":"2015","journal-title":"Endocrine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s12020-016-0958-x","article-title":"Hyperinsulinemia and obese phenotype differently influence blood pressure in young normotensive patients with polycystic ovary syndrome","volume":"55","author":"Mioni","year":"2017","journal-title":"Endocrine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3109\/09513590009167709","article-title":"Polycystic ovary syndrome: An endocrine and metabolic disease","volume":"14","author":"Scarpitta","year":"2000","journal-title":"Gynecol. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril., 81, 19\u201325.","DOI":"10.1016\/j.fertnstert.2003.10.004"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1210\/jc.2009-2724","article-title":"Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society","volume":"95","author":"Wild","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.4158\/EP15748.DSCPT2","article-title":"American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome-Part 2","volume":"21","author":"Goodman","year":"2015","journal-title":"Endocr. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e17126","DOI":"10.2196\/17126","article-title":"Lifestyle interventions for polycystic ovary syndrome: Cross-sectional survey to assess women\u2019s treatment and outcome preferences","volume":"4","author":"Saslow","year":"2020","journal-title":"JMIR Form. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/humrep\/deq068","article-title":"Psychological well-being and sexarche in women with polycystic ovary syndrome","volume":"25","author":"Pastoor","year":"2010","journal-title":"Hum. Reprod."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1530\/eje.1.02024","article-title":"Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome","volume":"153","author":"Hahn","year":"2005","journal-title":"Eur. J. Endocrinol."},{"key":"ref_32","first-page":"1298","article-title":"Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2","volume":"25","author":"Shet","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0015-0282(16)56518-2","article-title":"Comparison of flutamide and spironolactone in the treatment of hirsutism: A randomized controlled trial","volume":"61","author":"Cusan","year":"1994","journal-title":"Fertil. Steril."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0015-0282(16)54897-3","article-title":"Treatment of hirsutism in women with flutamide","volume":"57","author":"Marcondes","year":"1992","journal-title":"Fertil. Steril."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1665-2681(19)31595-9","article-title":"Acute and fulminant hepatitis induced by flutamide: Case series report and review of the literature","volume":"10","author":"Brahm","year":"2011","journal-title":"Ann. Hepatol."},{"key":"ref_36","first-page":"69","article-title":"Flutamide-induced hepatotoxicity: Ethical and scientific issues","volume":"21","author":"Giorgetti","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1310\/hpj4906-517","article-title":"Flutamide: Hirsutism in women","volume":"49","author":"Generali","year":"2014","journal-title":"Hosp. Pharm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrendo.2010.119","article-title":"Therapy: Low-dose flutamide for hirsutism: Into the limelight, at last","volume":"6","year":"2010","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1530\/EJE-10-0100","article-title":"Retrospective observational study on the effects and tolerability of flutamide in a large population of patients with various kinds of hirsutism over a 15-year period","volume":"163","author":"Paradisi","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.fertnstert.2008.01.046","article-title":"Long-term safety and tolerability of flutamide for the treatment of hirsutism","volume":"91","author":"Moyano","year":"2009","journal-title":"Fertil. Steril."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1210\/jcem.83.8.5041","article-title":"The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome","volume":"83","author":"Mitrakou","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/09513590400004736","article-title":"Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: A randomized prospective study","volume":"19","author":"Sahin","year":"2004","journal-title":"Gynecol. Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2265.2004.01973.x","article-title":"Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome","volume":"60","author":"Gambineri","year":"2004","journal-title":"Clin. Endocrinol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/humupd\/dmi054","article-title":"Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women","volume":"12","year":"2006","journal-title":"Hum. Reprod. Update"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.7326\/0003-4819-126-1-199701010-00005","article-title":"Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization","volume":"126","author":"Birdsall","year":"1997","journal-title":"Ann. Int. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0735-1097(98)00416-1","article-title":"Vascular reactivity is impaired in genetic females taking high-dose androgens","volume":"32","author":"McCredie","year":"1998","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ajog.2004.09.008","article-title":"Antihypertensive effects of flutamide in rats that are exposed to a low-protein diet in utero","volume":"192","author":"Gangula","year":"2005","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1210\/en.2015-1159","article-title":"Hyperandrogenism and insulin resistance, not changes in body weight, mediate the development of endothelial dysfunction in a female rat model of polycystic ovary syndrome (PCOS)","volume":"156","author":"Hurliman","year":"2015","journal-title":"Endocrinology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S0015-0282(02)03101-1","article-title":"The antiandrogenic effect of flutamide improves uterine perfusion in women with polycystic ovary syndrome","volume":"77","author":"Ajossa","year":"2002","journal-title":"Fertil. Steril."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1517\/14740338.2014.966686","article-title":"Safety of antiandrogen therapy for treating prostate cancer","volume":"13","author":"Ricci","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.jaad.2020.03.034","article-title":"Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients","volume":"83","author":"Ismail","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_52","first-page":"283","article-title":"Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance","volume":"62","author":"Bahceci","year":"2004","journal-title":"Horm. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1210\/jc.2017-01186","article-title":"Combined oral contraception and bicalutamide in polycystic ovary syndrome and severe hirsutism: A double-blind randomized controlled trial","volume":"103","author":"Moretti","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1345\/aph.1G025","article-title":"Spironolactone for hirsutism in polycystic ovary syndrome","volume":"39","author":"Christy","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"ref_55","first-page":"CD000194","article-title":"Spironolactone versus placebo or in combination with steroids for hirsutism and\/or acne","volume":"15","author":"Brown","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_56","first-page":"89","article-title":"Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: A randomized, double blind, placebo-controlled trial","volume":"85","author":"Moghetti","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2265.2000.00982.x","article-title":"Spironolactone as a single agent for long-term therapy of hirsute patients","volume":"52","author":"Spritzer","year":"2000","journal-title":"Clin. Endocrinol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1080\/14656566.2016.1215430","article-title":"Spironolactone in the treatment of polycystic ovary syndrome","volume":"17","author":"Armanini","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1530\/EJE-10-0709","article-title":"Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome","volume":"164","author":"Studen","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1097\/HJH.0b013e3283630362","article-title":"Arterial stiffness is increased in asymptomatic nondiabetic postmenopausal women with a polycystic ovary syndrome phenotype","volume":"31","author":"Armeni","year":"2013","journal-title":"J. Hypertens"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/01.ATV.0000160548.78317.29","article-title":"Mechanisms, pathophysiology, and therapy of arterial stiffness","volume":"25","author":"Zieman","year":"2005","journal-title":"Arterioscler Thromb. Vasc Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/jch.13385","article-title":"Vascular compliance in women with polycystic ovary syndrome treated with spironolactone","volume":"20","author":"Co","year":"2018","journal-title":"J. Clin. Hypertens"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJM198709243171307","article-title":"The use of ketoconazole as an inhibitor of steroid production","volume":"317","author":"Sonino","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1210\/jcem-61-4-718","article-title":"Prolonged treatment of Cushing\u2019s disease by ketoconazole","volume":"61","author":"Sonino","year":"1985","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0026-0495(90)90010-A","article-title":"Effect of ketoconazole on plasma sex hormones, lipids, lipoproteins, and apolipoproteins in hyperandrogenic women","volume":"39","author":"Cedeno","year":"1990","journal-title":"Metabolism"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0016-5085(84)80021-9","article-title":"Hepatic injury associated with ketoconazole therapy\u2013analysis of 33 cases","volume":"86","author":"Lewis","year":"1984","journal-title":"Gastroenterology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/ijd.14370","article-title":"The efficacy and use of finasteride in women: A systematic review","volume":"58","author":"Hu","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/09513590701214463","article-title":"Effect of finasteride 5 mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone","volume":"23","author":"Kohler","year":"2007","journal-title":"Gynecol. Endocrinol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/09513599709152542","article-title":"Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome","volume":"11","author":"Falsetti","year":"1997","journal-title":"Gynecol. Endocrinol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/gye.17.1.57.63","article-title":"The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism","volume":"17","author":"Lakryc","year":"2003","journal-title":"Gynecol. Endocrinol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1161\/CIRCULATIONAHA.114.012066","article-title":"Antiandrogenic therapy with finasteride attenuates cardiac hypertrophy and left ventricular dysfunction","volume":"131","author":"Zwadlo","year":"2015","journal-title":"Circulation"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.yjmcc.2018.08.011","article-title":"Anti-androgenic therapy with finasteride improves cardiac function, attenuates remodeling and reverts pathologic gene-expression after myocardial infarction in mice","volume":"122","author":"Froese","year":"2018","journal-title":"J. Mol. Cell Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1210\/jcem.84.4.5591","article-title":"A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism","volume":"84","author":"Venturoli","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_74","first-page":"84","article-title":"Comparison of finasteride, metformin, and finasteride plus metformin in PCOS","volume":"13","author":"Diri","year":"2017","journal-title":"Acta Endocrinol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s12020-014-0403-y","article-title":"Metformin in women with PCOS, pros","volume":"48","author":"Pasquali","year":"2015","journal-title":"Endocrine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2042018820938305","DOI":"10.1177\/2042018820938305","article-title":"A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome","volume":"11","author":"Abdalla","year":"2020","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1210\/jcem.85.8.6738","article-title":"Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome","volume":"85","author":"Pasquali","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/humupd\/dmv025","article-title":"Metformin and lifestyle modification in polycystic ovary syndrome: Systematic review and meta-analysis","volume":"21","author":"Naderpoor","year":"2015","journal-title":"Hum. Reprod. Update"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1210\/jc.2013-2385","article-title":"Lifestyle modification programs in polycystic ovary syndrome: Systematic review and meta- analysis","volume":"98","author":"Domecq","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1210\/jc.2007-0441","article-title":"Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome","volume":"92","author":"Palomba","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1517\/14728220903190699","article-title":"Targeting insulin sensitivity in the treatment of polycystic ovary syndrome","volume":"13","author":"Pasquali","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_84","first-page":"CD01350","article-title":"Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome","volume":"12","author":"Sharpe","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/CS20110386","article-title":"Cellular and molecular mechanisms of metformin: An overview","volume":"122","author":"Viollet","year":"2012","journal-title":"Clin. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3389\/fendo.2018.00284","article-title":"Diabetes mellitus secondary to Cushing\u2019s disease","volume":"9","author":"Barbot","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1080\/17425255.2016.1206887","article-title":"Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease","volume":"12","author":"Bizzarri","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1054-3589(08)60932-1","article-title":"Insulin mediators and the mechanism of insulin action","volume":"24","author":"Romero","year":"1993","journal-title":"Adv. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/09513590.2015.1054802","article-title":"Reflections on inositol(s) for PCOS therapy: Steps toward success","volume":"31","author":"Nestler","year":"2015","journal-title":"Gynecol. Endocrinol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/09513590.2017.1421632","article-title":"The use of inositol(s) isomers in the management of polycystic ovary syndrome: A comprehensive review","volume":"34","author":"Gateva","year":"2018","journal-title":"Gynecol. Endocrinol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2337\/diacare.29.02.06.dc05-1070","article-title":"Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome","volume":"29","author":"Baillargeon","year":"2006","journal-title":"Diabetes Care."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/humrep\/den097","article-title":"Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism","volume":"23","author":"Baillargeon","year":"2008","journal-title":"Hum. Reprod."},{"key":"ref_93","first-page":"47","article-title":"D-chiro-inositol\u2013its functional role in insulin action and its deficit in insulin resistance","volume":"3","author":"Larner","year":"2002","journal-title":"Int. J. Exp. Diabetes Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJM199904293401703","article-title":"Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome","volume":"340","author":"Nestler","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4158\/EP.8.6.417","article-title":"Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome","volume":"8","author":"Iuorno","year":"2002","journal-title":"Endocr. Pract."},{"key":"ref_96","first-page":"347","article-title":"Randomized, double blind placebo-controlled trial: Effects of myo-inositol on ovarian function and metabolic factors in women with PCOS","volume":"11","author":"Gerli","year":"2007","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/09513590801893232","article-title":"Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome","volume":"24","author":"Genazzani","year":"2008","journal-title":"Gynecol. Endocrinol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1530\/EJE-11-0840","article-title":"Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome","volume":"166","author":"Sabbadin","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/humrep\/17.6.1591","article-title":"Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: Relationship with oocyte quality","volume":"17","author":"Chiu","year":"2002","journal-title":"Hum. Reprod."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.fertnstert.2008.01.088","article-title":"Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles\u2013a prospective, controlled, randomized trial","volume":"91","author":"Papaleo","year":"2009","journal-title":"Fertil. Steril."},{"key":"ref_101","first-page":"452","article-title":"Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles\u2013a prospective, controlled, randomized trial","volume":"15","author":"Unfer","year":"2011","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1757-2215-5-14","article-title":"CONCERN: Does ovary need D-chiro-inositol?","volume":"5","author":"Isabella","year":"2012","journal-title":"J. Ovarian Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/humrep\/deh609","article-title":"Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries","volume":"20","author":"Rice","year":"2005","journal-title":"Hum. Reprod"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.fertnstert.2011.05.027","article-title":"The D-chiro-inositol paradox in the ovary","volume":"95","author":"Carlomagno","year":"2011","journal-title":"Fertil. Steril."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.tem.2020.02.002","article-title":"Group of \u2018Inositol in PCOS and Reproduction\u2019. Inositols in polycystic ovary syndrome: An overview on the advances","volume":"31","author":"Facchinetti","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_106","first-page":"87","article-title":"The role of inositols in PCOS\u2013opinion paper","volume":"31","author":"Scambia","year":"2019","journal-title":"Ital. J. Gynecol. Obstet."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3109\/09513590.2016.1144741","article-title":"Inositol\u2019s and other nutraceuticals\u2019 synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: State-of-the-art and future perspectives","volume":"32","author":"Paul","year":"2016","journal-title":"Gynecol. Endocrinol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/09513590.2018.1540578","article-title":"Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): A meta-analysis of randomized clinical trials","volume":"35","author":"Facchinetti","year":"2019","journal-title":"Gynecol. Endocrinol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/09513590.2018.1549656","article-title":"Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: Randomized controlled trial","volume":"35","author":"Agrawal","year":"2019","journal-title":"Gynecol. Endocrinol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1473612","DOI":"10.1155\/2016\/1473612","article-title":"Myo-inositol in the treatment of teenagers affected by PCOS","volume":"2016","author":"Pkhaladze","year":"2016","journal-title":"Int. J. Endocrinol."},{"key":"ref_111","first-page":"2633494120908709","article-title":"What is new in the landscape of insulin-sensitizing agents for polycystic ovary syndrome treatment","volume":"14","author":"Romualdi","year":"2020","journal-title":"Ther. Adv. Reprod. Health"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/09513590.2018.1540573","article-title":"Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome","volume":"35","author":"Fruzzetti","year":"2019","journal-title":"Gynecol. Endocrinol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1080\/09513590.2019.1640200","article-title":"Differential insulin response to oral glucose tolerance test (OGTT) in overweight\/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both","volume":"35","author":"Genazzani","year":"2019","journal-title":"Gynecol. Endocrinol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/jhrs.JHRS_74_16","article-title":"The effect of metformin treatment on the serum levels of homocysteine, folic acid, and vitamin B12 in patients with polycystic ovary syndrome","volume":"10","author":"Esmaeilzadeh","year":"2017","journal-title":"J. Hum. Reprod. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","article-title":"Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): A randomised, double-blind, placebo-controlled trial","volume":"5","author":"Holman","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/s-0034-1375676","article-title":"Effects of acarbose on polycystic ovary syndrome: A meta-analysis","volume":"122","author":"Zhang","year":"2014","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.fertnstert.2006.11.073","article-title":"Cardiovascular risk factors are reduced with a low dose of acarbose in obese patients with polycystic ovary syndrome","volume":"88","author":"Canella","year":"2007","journal-title":"Fertil. Steril."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.fertnstert.2007.07.1326","article-title":"Clinical, endocrine, and metabolic effects of acarbose, a alpha-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome","volume":"90","author":"Kutlu","year":"2008","journal-title":"Fertil. Steril."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/humrep\/dei104","article-title":"Acarbose in obese patients with polycystic ovarian syndrome: A double-blind, randomized, placebo-controlled study","volume":"20","author":"Penna","year":"2005","journal-title":"Hum. Reprod."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/humrep\/16.10.2066","article-title":"Clinical, endocrine and metabolic effects of acarbose, an alpha-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance","volume":"16","author":"Ciotta","year":"2001","journal-title":"Hum. Reprod."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/humrep\/deg343","article-title":"Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin","volume":"18","author":"Glueck","year":"2003","journal-title":"Hum. Reprod."},{"key":"ref_122","first-page":"CD003053","article-title":"Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome","volume":"3","author":"Lord","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1210\/jc.2003-031737","article-title":"Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome","volume":"89","author":"Brettenthaler","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1677\/joe.1.05844","article-title":"Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome","volume":"184","author":"Cardoza","year":"2005","journal-title":"J. Endocrinol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00404-017-4480-z","article-title":"Comparison of the effect between pioglitazone and metformin in treating patients with PCOS: A meta-analysis","volume":"296","author":"Xu","year":"2017","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1592\/phco.25.2.244.56943","article-title":"Thiazolidinediones for treatment of polycystic ovary syndrome","volume":"25","author":"Stout","year":"2005","journal-title":"Pharmacotherapy"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"16767","DOI":"10.1074\/jbc.M100040200","article-title":"Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3\u03b2-hydroxysteroid dehydrogenase","volume":"276","author":"Arlt","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11154-019-09536-6","article-title":"The pathogenic role of the GIP\/GIPR axis in human endocrine tumors: Emerging clinical mechanisms beyond diabetes","volume":"21","author":"Regazzo","year":"2020","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-13-0797","article-title":"Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin","volume":"170","author":"Kocjan","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e2695","DOI":"10.1210\/clinem\/dgaa285","article-title":"Obesity, polycystic ovary syndrome, and infertility: A new avenue for GLP-1 receptor agonists","volume":"105","author":"Cena","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fendo.2014.00140","article-title":"The effect of liraglutide on weight loss in women with polycystic ovary syndrome: An observational study","volume":"5","author":"Rasmussen","year":"2014","journal-title":"Front. Endocrinol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3892\/etm.2016.3081","article-title":"Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study","volume":"11","author":"Jensterle","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Kahal, H., Aburima, A., Ungvari, T., Rigby, A.S., Coady, A.M., Vince, R.V., Ajjan, R.A., Kilpatrick, E.S., Naseem, K.M., and Atkin, S.L. (2015). The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. BMC Endocr. Disord., 15.","DOI":"10.1186\/s12902-015-0005-6"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EC-16-0113","article-title":"Liraglutide in polycystic ovary syndrome: A randomized trial, investigating effects on thrombogenic potential","volume":"6","author":"Nylander","year":"2017","journal-title":"Endocr. Connect."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Jensterle, M., Kravos, N.A., Gori\u010dar, K., and Janez, A. (2017). Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: Randomized trial. BMC Endocr. Disord., 17.","DOI":"10.1186\/s12902-017-0155-9"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1210\/jc.2008-0115","article-title":"Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome","volume":"93","author":"Marrioneaux","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fendo.2019.00189","article-title":"The effect of exenatide on cardiovascular risk markers in women with polycystic ovary syndrome","volume":"10","author":"Dawson","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/cen.14056","article-title":"Changes in whole metabolites after exenatide treatment in overweight\/obese polycystic ovary syndrome patients","volume":"91","author":"Tang","year":"2019","journal-title":"Clin. Endocrinol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/cen.13454","article-title":"Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight\/obese polycystic ovary syndrome","volume":"87","author":"Liu","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomized placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Tao, T., Wu, P., Wang, Y., and Liu, W. (2018). Comparison of glycemic control and \u03b2-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment. BMC Endocr. Disord., 18.","DOI":"10.1186\/s12902-018-0243-5"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1089\/met.2017.0095","article-title":"Dipeptidyl peptidase-4 inhibitor sitagliptin prevented weight regain in obese women with polycystic ovary syndrome previously treated with liraglutide: A pilot randomized study","volume":"15","author":"Ferjan","year":"2017","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"dgz028","DOI":"10.1210\/clinem\/dgz028","article-title":"Sitagliptin decreases visceral fat and blood glucose in women with polycystic ovarian syndrome","volume":"105","author":"Devin","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4158\/EP-2017-0027","article-title":"DPP4 inhibitor sitagliptin as a potential treatment option in metformin-intolerant obese women with polycystic ovary syndrome: A pilot randomized study","volume":"24","author":"Ferjan","year":"2018","journal-title":"Endocr. Pract."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13300-014-0089-4","article-title":"Sodium glucose co-transporter-2 (SGLT2) inhibitors: A review of their basic and clinical pharmacology","volume":"5","author":"Kalra","year":"2014","journal-title":"Diabetes Ther."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1530\/EC-20-0173","article-title":"The effects of empagliflozin vs metformin on endothelial microparticles in overweight\/obese women with polycystic ovary syndrome","volume":"9","author":"Javed","year":"2020","journal-title":"Endocr. Connect."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/cen.13968","article-title":"Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study","volume":"90","author":"Javed","year":"2019","journal-title":"Clin. Endocrinol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.fertnstert.2016.10.027","article-title":"Noncontraceptive use of oral combined hormonal contraceptives in polycystic ovary syndrome-risks versus benefits","volume":"106","author":"Dokras","year":"2016","journal-title":"Fertil. Steril."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12958-017-0313-y","article-title":"Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome","volume":"15","year":"2017","journal-title":"Reprod. Biol. Endocrinol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.steroids.2013.04.009","article-title":"Cardiovascular disease risk in women with PCOS","volume":"78","author":"Dokras","year":"2013","journal-title":"Steroids"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1210\/jc.2016-2586","article-title":"Hyperandrogenism accompanies increased intra-abdominal fat storage in normal weight polycystic ovary syndrome women","volume":"101","author":"Dumesic","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_156","first-page":"CD010813","article-title":"Combined oral contraceptives: Venous thrombosis","volume":"3","author":"Stegeman","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.fertnstert.2016.08.039","article-title":"Hormonal contraception and thrombosis","volume":"106","year":"2016","journal-title":"Fertil. Steril."},{"key":"ref_158","first-page":"1","article-title":"The influence of female sex steroids on glucose metabolism and insulin action","volume":"738","author":"Godsland","year":"1996","journal-title":"J. Int. Med. Suppl."},{"key":"ref_159","first-page":"3161","article-title":"Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: A randomized study","volume":"85","author":"Vauhkonen","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/humrep\/deq301","article-title":"The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: A systematic review and meta-analysis of observational studies","volume":"26","author":"Halperin","year":"2011","journal-title":"Hum. Reprod."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1210\/jc.2015-2778","article-title":"Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome","volume":"100","author":"Legro","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/humrep\/deh329","article-title":"Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: Switch from third- to fourth-generation OC reduces body adiposity","volume":"19","author":"Ibanez","year":"2004","journal-title":"Hum. Reprod."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0010-7824(96)00195-3","article-title":"The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and antiandrogenic potential","volume":"54","author":"Fuhrmann","year":"1996","journal-title":"Contraception"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3109\/09513590.2015.1006187","article-title":"Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up","volume":"31","author":"Yildizhan","year":"2015","journal-title":"Gynecol. Endocrinol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09513590.2017.1381681","article-title":"The cardiometabolic effect of current management of polycystic ovary syndrome: Strategies of prevention and treatment","volume":"34","author":"Skrgatic","year":"2018","journal-title":"Gynecol. Endocrinol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3389\/fendo.2019.00575","article-title":"Aldosterone in gynecology and its involvement on the risk of hypertension in pregnancy","volume":"10","author":"Sabbadin","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/humupd\/dmx039","article-title":"Combined oral contraceptives and\/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: A systematic review and meta-analysis","volume":"24","year":"2018","journal-title":"Hum. Reprod. Update"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.steroids.2012.02.010","article-title":"Polycystic ovary syndrome: Implications of measurement of plasma aldosterone, renin activity and progesterone","volume":"77","author":"Armanini","year":"2012","journal-title":"Steroids"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1210\/jc.2006-0399","article-title":"Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome","volume":"91","author":"Cascella","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_170","first-page":"55","article-title":"Hypertension in polycystic ovary syndrome: Novel insights","volume":"16","author":"Macut","year":"2020","journal-title":"Curr. Hypertens Rev."},{"key":"ref_171","first-page":"315","article-title":"Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism","volume":"10","author":"Bastianelli","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/17425255.2016.1190832","article-title":"Metabolic impact of combined hormonal contraceptives containing estradiol","volume":"12","author":"Grandi","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3109\/09513590.2013.831834","article-title":"Effects of an oral contraceptive containing estradiol valerate and dienogest on circulating androgen levels and acne in young patients with PCOS: An observational preliminary study","volume":"29","author":"Gargano","year":"2013","journal-title":"Gynecol. Endocrinol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.contraception.2012.09.003","article-title":"Effect of a new oral contraceptive with estradiol valerate\/dienogest on carbohydrate metabolism","volume":"88","author":"Fruzzetti","year":"2013","journal-title":"Contraception"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1210\/jc.2018-00241","article-title":"Evaluation and treatment of hirsutism in premenopausal women: An Endocrine Society clinical practice guideline","volume":"103","author":"Martin","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/09513590.2017.1418853","article-title":"Evaluation of prolonged use of statins on the clinical and biochemical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome","volume":"34","author":"Seyam","year":"2018","journal-title":"Gynecol. Endocrinol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1530\/EC-17-0217","article-title":"The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome","volume":"6","author":"Sathyapalan","year":"2017","journal-title":"Endocr. Connect."},{"key":"ref_178","first-page":"47","article-title":"The gender-specific clinical pharmacology of statins: An update","volume":"4","author":"Cignarella","year":"2018","journal-title":"Ital. J. Gend. Specif. Med."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Almalki, H.H., Alshibani, T.M., Alhifany, A.A., and Almohammed, O.A. (2020). Comparative efficacy of statins, metformin, spironolactone and combined oral contraceptives in reducing testosterone levels in women with polycystic ovary syndrome: A network meta-analysis of randomized clinical trials. BMC Womens Health, 20.","DOI":"10.1186\/s12905-020-00919-5"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.repbio.2019.09.006","article-title":"Current and future aspects of several adjunctive treatment strategies in polycystic ovary syndrome","volume":"19","author":"Banaszewska","year":"2019","journal-title":"Reprod. Biol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3389\/fendo.2019.00394","article-title":"The effect of atorvastatin (and subsequent metformin) on adipose tissue acylation-stimulatory-protein concentration and inflammatory biomarkers in overweight\/obese women with polycystic ovary syndrome","volume":"10","author":"Sathyapalan","year":"2019","journal-title":"Front Endocrinol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/OAJC.S179673","article-title":"Venous thrombosis and hormonal contraception: What\u2019s new with estradiol-based hormonal contraceptives?","volume":"9","author":"Fruzzetti","year":"2018","journal-title":"Open Access J. Contracept."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/humupd\/dmw016","article-title":"Hormonal contraceptives: Pharmacology tailored to women\u2019s health","volume":"22","author":"Musacchio","year":"2016","journal-title":"Hum. Reprod. Update"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.fertnstert.2008.09.070","article-title":"Long-term consequences of polycystic ovary syndrome on cardiovascular risk","volume":"91","author":"Rizzo","year":"2009","journal-title":"Fertil. Steril."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0895-4356(98)00035-3","article-title":"Mortality of women with polycystic ovary syndrome at long-term follow-up","volume":"51","author":"Pierpoint","year":"1998","journal-title":"J. Clin. Epidemiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/24\/9554\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:45:28Z","timestamp":1760179528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/24\/9554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":185,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["ijms21249554"],"URL":"https:\/\/doi.org\/10.3390\/ijms21249554","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,15]]}}}